Published in Int J Physiol Pathophysiol Pharmacol on November 15, 2011
Epigenetic regulation of aortic remodeling in hyperhomocysteinemia. FASEB J (2014) 0.87
Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta (2000) 5.39
Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev (1999) 4.75
Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA (2008) 4.49
Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci (2002) 4.23
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest (1999) 3.35
Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum (2001) 3.08
Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal (2008) 2.97
Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science (2009) 2.82
Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques (2005) 2.55
Arterial-venous specification during development. Circ Res (2009) 2.49
TIMPs as multifacial proteins. Crit Rev Oncol Hematol (2004) 2.18
TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol (2000) 2.17
Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis (1999) 2.06
Homocysteine enhances endothelial apoptosis via upregulation of Fas-mediated pathways. Hypertension (2004) 1.76
Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia. Am J Physiol Endocrinol Metab (2010) 1.74
Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke (2004) 1.57
Folic acid improves acetylcholine-induced vasoconstriction of coronary vessels isolated from hyperhomocysteinemic mice: an implication to coronary vasospasm. J Cell Physiol (2011) 1.54
[Metalloproteases, vascular remodeling and atherothrombotic syndromes]. Rev Esp Cardiol (2007) 1.48
Collagens in the progression and complications of atherosclerosis. Vasc Med (2009) 1.47
Fluid shear stress induces arterial differentiation of endothelial progenitor cells. J Appl Physiol (1985) (2008) 1.46
Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. Am J Physiol Renal Physiol (2009) 1.43
Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation (1999) 1.41
Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res (2004) 1.30
Vascular complications of cystathionine β-synthase deficiency: future directions for homocysteine-to-hydrogen sulfide research. Am J Physiol Heart Circ Physiol (2010) 1.23
Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem (2002) 1.22
Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis. Am J Nephrol (2010) 1.16
MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem (2010) 1.12
Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells. Blood (2002) 1.12
MicroRNAs are involved in homocysteine-induced cardiac remodeling. Cell Biochem Biophys (2009) 1.11
Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implications. Cardiovasc Res (2000) 1.07
Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol (1993) 1.06
Homocysteine to hydrogen sulfide or hypertension. Cell Biochem Biophys (2010) 1.05
Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol Chem (2003) 1.04
Homocysteine stimulates NADPH oxidase-mediated superoxide production leading to endothelial dysfunction in rats. Can J Physiol Pharmacol (2007) 1.04
Brothers and sisters: molecular insights into arterial-venous heterogeneity. Circ Res (2008) 1.03
Functional consequences of the collagen/elastin switch in vascular remodeling in hyperhomocysteinemic wild-type, eNOS-/-, and iNOS-/- mice. Am J Physiol Lung Cell Mol Physiol (2010) 1.01
EphB4 expression along adult rat microvascular networks: EphB4 is more than a venous specific marker. Microcirculation (2007) 1.01
Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. J Pathol (2002) 1.00
Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance. Am J Physiol Endocrinol Metab (2008) 1.00
Hydrogen sulfide mitigates matrix metalloproteinase-9 activity and neurovascular permeability in hyperhomocysteinemic mice. Neurochem Int (2009) 0.98
Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am J Physiol (1998) 0.98
Mesenteric vascular remodeling in hyperhomocysteinemia. Mol Cell Biochem (2010) 0.96
Collagen and elastin cross-linking: a mechanism of constrictive remodeling after arterial injury. Am J Physiol Heart Circ Physiol (2005) 0.95
Homocysteine induces metalloproteinase and shedding of beta-1 integrin in microvessel endothelial cells. J Cell Biochem (2004) 0.94
Effects of homocysteine on proliferation, necrosis, and apoptosis of vascular smooth muscle cells in culture and influence of folic acid. Thromb Res (2001) 0.94
Blood flow interplays with elastin: collagen and MMP: TIMP ratios to maintain healthy vascular structure and function. Vasc Health Risk Manag (2010) 0.93
Homocysteine and essential hypertension. J Clin Pharmacol (2003) 0.93
Ephrin B2/EphB4 pathway in hepatic stellate cells stimulates Erk-dependent VEGF production and sinusoidal endothelial cell recruitment. Am J Physiol Gastrointest Liver Physiol (2010) 0.91
Vascular wall resident progenitor cells: a review. Exp Cell Res (2009) 0.90
Endothelial ephrinB2 is controlled by microenvironmental determinants and associates context-dependently with CD31. Arterioscler Thromb Vasc Biol (2005) 0.90
Homocysteine and pulsatility index of cerebral arteries. Stroke (2009) 0.87
Oxidative mechanism and homeostasis of proteinase/antiproteinase in congestive heart failure. J Mol Cell Cardiol (2006) 0.86
Protective role of mast cells in homocysteine-induced cardiac remodeling. Am J Physiol Heart Circ Physiol (2004) 0.84
Epithelial expression of TIMP-1 does not alter sensitivity to bleomycin-induced lung injury in C57BL/6 mice. Am J Physiol Lung Cell Mol Physiol (2008) 0.84
Homocysteine modulates the proteolytic potential of human arterial smooth muscle cells through a reactive oxygen species dependant mechanism. Mol Cell Biochem (2009) 0.83
Homocysteine is the only plasma thiol associated with carotid artery remodeling. Atherosclerosis (2002) 0.83
Homocysteine-dependent endothelial dysfunction induced by renal ischemia/reperfusion injury. J Nephrol (2011) 0.82
Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol (2008) 0.81
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond) (2004) 2.13
Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol (2002) 1.76
Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens (2003) 1.71
Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol (2005) 1.68
MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med (2009) 1.67
Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem (2005) 1.59
Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol (2005) 1.59
Folic acid improves acetylcholine-induced vasoconstriction of coronary vessels isolated from hyperhomocysteinemic mice: an implication to coronary vasospasm. J Cell Physiol (2011) 1.54
Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced Type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol (2006) 1.50
Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol (2002) 1.46
Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. Am J Physiol Renal Physiol (2009) 1.43
Folic acid improves inner ear vascularization in hyperhomocysteinemic mice. Hear Res (2011) 1.42
Homocysteine causes cerebrovascular leakage in mice. Am J Physiol Heart Circ Physiol (2005) 1.35
Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J Exp Med (2007) 1.32
H2S protects against methionine-induced oxidative stress in brain endothelial cells. Antioxid Redox Signal (2009) 1.30
Mitochondrial division/mitophagy inhibitor (Mdivi) ameliorates pressure overload induced heart failure. PLoS One (2012) 1.28
Hydrogen sulfide mitigates cardiac remodeling during myocardial infarction via improvement of angiogenesis. Int J Biol Sci (2012) 1.27
H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure. Am J Physiol Heart Circ Physiol (2009) 1.23
Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway. Am J Physiol Cell Physiol (2005) 1.22
Cystathionine-beta-synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells. Am J Physiol Cell Physiol (2007) 1.22
Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure. J Appl Physiol (1985) (2011) 1.18
Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol (2008) 1.17
Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis. Am J Nephrol (2010) 1.16
Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxid Redox Signal (2011) 1.16
Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice. J Appl Physiol (1985) (2005) 1.14
Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J Cell Biochem (2006) 1.14
The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol (2005) 1.14
Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol (2002) 1.14
In utero arsenic exposure induces early onset of atherosclerosis in ApoE-/- mice. Reprod Toxicol (2007) 1.14
Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. Am J Physiol Heart Circ Physiol (2006) 1.13
MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem (2010) 1.12
MicroRNAs are involved in homocysteine-induced cardiac remodeling. Cell Biochem Biophys (2009) 1.11
Homocysteine decreases blood flow to the brain due to vascular resistance in carotid artery. Neurochem Int (2008) 1.11
Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol (2004) 1.11
Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus. Am J Physiol Renal Physiol (2006) 1.10
Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens (2002) 1.10
Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutr J (2004) 1.07
Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR. Am J Physiol Cell Physiol (2002) 1.06
Protease-activated receptor and endothelial-myocyte uncoupling in chronic heart failure. Am J Physiol Heart Circ Physiol (2005) 1.06
Early induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure. J Cell Mol Med (2005) 1.06
Type 2 diabetes mellitus as a conformational disease. JOP (2005) 1.06
Homocysteine to hydrogen sulfide or hypertension. Cell Biochem Biophys (2010) 1.05
Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes (2013) 1.05
Hydrogen sulfide protects against vascular remodeling from endothelial damage. Amino Acids (2010) 1.05
Fibrinogen induces endothelial cell permeability. Mol Cell Biochem (2007) 1.05
MMP-9 gene ablation and TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: a plausible role of dicer and miRNA. Cell Biochem Biophys (2010) 1.04
Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer. Circulation (2004) 1.04
Nutri-epigenetics ameliorates blood-brain barrier damage and neurodegeneration in hyperhomocysteinemia: role of folic acid. J Mol Neurosci (2014) 1.03
Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia. J Cell Physiol (2008) 1.02
Functional consequences of the collagen/elastin switch in vascular remodeling in hyperhomocysteinemic wild-type, eNOS-/-, and iNOS-/- mice. Am J Physiol Lung Cell Mol Physiol (2010) 1.01
GABA receptors ameliorate Hcy-mediated integrin shedding and constrictive collagen remodeling in microvascular endothelial cells. Cell Biochem Biophys (2006) 1.00
Cardioprotective role of sodium thiosulfate on chronic heart failure by modulating endogenous H2S generation. Pharmacology (2008) 1.00
gamma-Aminbuturic acid A receptor mitigates homocysteine-induced endothelial cell permeability. Endothelium (2007) 1.00
Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance. Am J Physiol Endocrinol Metab (2008) 1.00
Synergy of homocysteine, microRNA, and epigenetics: a novel therapeutic approach for stroke. Mol Neurobiol (2013) 1.00
Defective homocysteine metabolism: potential implications for skeletal muscle malfunction. Int J Mol Sci (2013) 0.99
Increased endogenous H2S generation by CBS, CSE, and 3MST gene therapy improves ex vivo renovascular relaxation in hyperhomocysteinemia. Am J Physiol Cell Physiol (2012) 0.99
Mitochondrial mechanism of oxidative stress and systemic hypertension in hyperhomocysteinemia. J Cell Biochem (2005) 0.99
Mechanisms of endothelial dysfunction with development of type 1 diabetes mellitus: role of insulin and C-peptide. J Cell Biochem (2005) 0.99
Differential expression of dicer, miRNAs, and inflammatory markers in diabetic Ins2+/- Akita hearts. Cell Biochem Biophys (2014) 0.98
Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol. Cardiovasc Diabetol (2010) 0.98
Nitrotyrosinylation, remodeling and endothelial-myocyte uncoupling in iNOS, cystathionine beta synthase (CBS) knockouts and iNOS/CBS double knockout mice. J Cell Biochem (2009) 0.98
Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch (2014) 0.98
Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol (2003) 0.98
Ablation of MMP9 induces survival and differentiation of cardiac stem cells into cardiomyocytes in the heart of diabetics: a role of extracellular matrix. Can J Physiol Pharmacol (2012) 0.98
Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy. J Immunol (2011) 0.98
Hydrogen sulfide mitigates matrix metalloproteinase-9 activity and neurovascular permeability in hyperhomocysteinemic mice. Neurochem Int (2009) 0.98
Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone. Int J Biol Sci (2007) 0.98
Fibrinogen-induced endothelin-1 production from endothelial cells. Am J Physiol Cell Physiol (2009) 0.97
Activation of GABA-A receptor ameliorates homocysteine-induced MMP-9 activation by ERK pathway. J Cell Physiol (2009) 0.97
Generation of nitrotyrosine precedes activation of metalloproteinase in myocardium of hyperhomocysteinemic rats. Antioxid Redox Signal (2002) 0.97
Lung ischemia-reperfusion injury: implications of oxidative stress and platelet-arteriolar wall interactions. Arch Physiol Biochem (2007) 0.97
Stem cells as a therapeutic target for diabetes. Front Biosci (Landmark Ed) (2010) 0.96
3-Deazaadenosine mitigates arterial remodeling and hypertension in hyperhomocysteinemic mice. Am J Physiol Lung Cell Mol Physiol (2006) 0.96
Extracellular matrix remodeling in the heart of the homocysteinemic obese rabbit. Am J Hypertens (2005) 0.95
Fibrinogen induces alterations of endothelial cell tight junction proteins. J Cell Physiol (2009) 0.95
Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation. Am J Physiol Cell Physiol (2002) 0.95